GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Kwality Pharmaceuticals Ltd

Kwality Pharma Q2 FY27 Consolidated Revenue Up 63% YoY to ₹181 Crore; Auditor Change

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 12 Nov 2026, 12:55 PM IST  ·  BSE ID: da65c6b3-460e-45fc-b52c-d7c3fc427c9f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported significantly higher revenue and doubled its profit for the latest quarter, and changed its auditors.
🤖 AI Summary
  • Kwality Pharmaceuticals Ltd. reported Q2 FY27 consolidated revenue of ₹181 crore, up 63% year-on-year.
  • Net profit for Q2 FY27 doubled to ₹50 crore, compared to ₹25 crore in Q2 FY26.
  • EBITDA margins expanded to 27.5% in Q2 FY27 from 23.4% in the corresponding prior quarter.
  • The Board approved the resignation of M/s. Vijay Mehra & Co. and appointed M/s. B S R & Co. LLP as Statutory Auditors.
  • The company revised its FY27 revenue guidance upwards to ₹720 crore+ from an earlier ₹700 crore.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Revenue Q2 FY27
₹181 crore
63%
Consolidated Revenue Q2 FY26
₹111 crore
Consolidated Net Profit Q2 FY27
₹50 crore
100%
Consolidated Net Profit Q2 FY26
₹25 crore
EBITDA Margin Q2 FY27
27.5%
EBITDA Margin Q2 FY26
23.4%
Revised FY27 Revenue Guidance
₹720 crore+
Previous FY27 Revenue Guidance
₹700 crore
Consolidated Revenue H1 FY27
₹343 crore
Debtor Days H1 FY27
178 days
Debtor Days FY26
203 days
Inventory Days H1 FY27
77 days
Inventory Days FY26
111 days
Cash Conversion Cycle H1 FY27
130 days
Cash Conversion Cycle FY26
170 days
🏢 How This Affects the Company
📈
Business Impact
The upward revision of FY27 revenue guidance to ₹720 crore+ indicates management's confidence in sustained growth and expanding market opportunities. Acquisitions of land for Unit 7 and EU-GMP certification for facilities strengthen manufacturing and regulatory footprint.
💰
Financial Impact
Consolidated revenue growth of 63% and PAT doubling to ₹50 crore reflect improved financial performance and profitability. Enhanced working capital efficiency, with debtor days reducing to 178 days and inventory days to 77 days in H1 FY27, improves cash generation.
⚙️
Operational Impact
The acquisition of 4 acres for Unit 7, EU-GMP certification for Cephalosporin and Oncology facilities, and completion of Hormone manufacturing facility construction expand operational capacity and capabilities. Advancement in global product development with 19 BE studies completed supports future product launches.
⚠️
Risk Impact
The change in Statutory Auditors from M/s. Vijay Mehra & Co. to M/s. B S R & Co. LLP is a governance-related event. The company stated no concerns were raised by the resigning auditor other than those in the resignation letter.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are indirectly affected by the company's financial performance and strategic decisions to expand manufacturing and strengthen governance through a new auditor appointment.
🔍
Management Signal
Management is signaling a focus on significant growth, operational expansion, improved profitability, and enhanced corporate governance through auditor change and revised guidance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor if revenue growth and margin expansion are sustained.
Announcement of General Meeting for approval of new Statutory Auditors.
Updates on the Unit 7 mega manufacturing facility development and commissioning timeline.
LOW RISK No material concerns raised by the resigning auditor were reported in the filing.
💡 Investor Takeaway
Kwality Pharmaceuticals delivered strong Q2 FY27 results with consolidated revenue up 63% year-on-year to ₹181 crore and net profit doubling to ₹50 crore. EBITDA margins expanded to 27.5%. The company revised its FY27 revenue guidance upwards to ₹720 crore+.
⚖️ Strengths & Concerns

✅ Positives

  • Q2 FY27 consolidated revenue grew 63% year-on-year to ₹181 crore, reflecting robust business momentum.
  • Net profit for Q2 FY27 doubled to ₹50 crore from ₹25 crore in Q2 FY26, with PAT margins expanding to 16%.
📅 Company Track Record
A previous filing on November 5, 2026, informed BSE that Kwality Pharmaceuticals Ltd. would hold a board meeting on November 12, 2026, to approve Q2 FY27 financial results.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Kwality Pharmaceuticals' consolidated revenue in Q2 FY27?
Kwality Pharmaceuticals Ltd.'s consolidated revenue for Q2 FY27 was ₹181 crore, representing a 63% year-on-year increase from ₹111 crore in Q2 FY26.
What was Kwality Pharmaceuticals' net profit in Q2 FY27?
Kwality Pharmaceuticals Ltd. reported a consolidated net profit of ₹50 crore for Q2 FY27, which doubled from ₹25 crore in the corresponding prior quarter, Q2 FY26.
What is the new FY27 revenue guidance for Kwality Pharmaceuticals?
Kwality Pharmaceuticals Ltd. revised its FY27 revenue guidance upwards to ₹720 crore+, from its earlier guidance of ₹700 crore.
Which audit firm was appointed as the new Statutory Auditor for Kwality Pharmaceuticals?
M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022), was appointed as the Statutory Auditors of Kwality Pharmaceuticals Ltd. to fill a casual vacancy, effective November 12, 2026.
How has Kwality Pharmaceuticals' working capital efficiency improved in H1 FY27?
In H1 FY27, Kwality Pharmaceuticals' debtor days reduced to 178 days from 203 days in FY26, and inventory days improved to 77 days from 111 days in FY26. The cash conversion cycle improved to 130 days from 170 days in FY26.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.